⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Joseph Markowitz Michael J. Shamblott Andrew S. Brohl Amod A. Sarnaik Zeynep Eroglu Nikhil I. Khushalani Christopher W. Dukes Alejandra Chamizo Marina Bastawrous Edward T. Garcia Ashraf Dehlawi Pei-Ling Chen Deanryan B. De Aquino Vernon K. Sondak Ahmad A. Tarhini Youngchul Kim Patricia Lawman Shari Pilon‐Thomas

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplemental Figure 2: Cytokine/chemokines increased or decreased after therapy in individual patients with the IO panel. The

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Markowitz et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574ca5 https://doi.org/10.1158/1535-7163.26423971

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
2Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
3Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
4Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
5Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
6Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
7Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024
8Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.02024